www.perpetualcommotion.com
"Give with a free hand, but give only your own."
-- J.R.R. Tolkien The Children of Hurin
- Clioquinol -
General Information:
Names:
Wikipedia entry:
Dr. Ray Shahelien entry:
********************************************************************************************
Observations:
Clioquinol
- An old drug with new
possibilities
********************************************************************************************
Known sources:
********************************************************************************************
Natural sources:
********************************************************************************************
References:
Clioquinol: metal chelator
A[beta] Metallobiology and the Development of Novel
Metal-Protein Attenuating
Compounds (MPACs) for Alzheimer's Disease
Cyril C. Curtain1, Kevin J. Barnham1 and Ashley I. Bush
"Abstract: Over a decade of studies have pointed to metal
mediated neural oxidative damage asan attractive target for the
treatment of Alzheimer’s disease. Because of the nature of the
blood brain barrier, systemic depletion of the metals, copper,
zinc and possibly iron, is not a viable approach. However
preliminary studies with CQ, a blood brain barrier penetrating
chelating agent, are showing promise. CQ probably works by
combining with the metal centres, primarily copper and zinc
complexes of Ab, in the neuropil. This review discusses some of
the background that resulted in CQ becoming a lead compound and
how we might advance our understanding of its action"
http://www.alzforum.org/res/for/journal/allsop/bush.pdf
PBT2 Demonstrates Rapid And
Potent Effects In Cognition, Reduction Of Brain Soluble
Beta-amyloid And Significant Improvement In Synaptic Function
20 Jul 2006
The observation that PBT1 (clioquinol)[2], a retired
anti-amoebic drug, could halt cognitive decline in a pilot Phase
IIa Alzheimer's patient study was the original catalyst for the
creation of Prana's new generation MPAC (Metal Protein
Attenuating Compound) chemical library. This platform of agents
may have therapeutic utility in several key neurological
disorders. Rodent pharmacokinetic studies have shown that the
brain concentration of PBT2 is about 50-fold greater than
clioquinol for an IV equivalent dose...
http://www.medicalnewstoday.com/articles/47696.php
Treating
protein
folding diseases
"Preventing aggregation is therefore a primary therapeutic
target, but
there is more than one stage that can be targeted. Strategies so
far
have focused on disrupting polymerization and fibril
aggregation. These
include using low-molecular-weight substances such as congo red
dye,
the antibiotic rifampicin, peptides that bind to amyloid-b
peptide and drugs that chelate metals such as copper and zinc,
which
themselves accelerate amyloid-b deposition. Indeed, interim
results
from a placebo-controlled trial of the antibiotic
iodochlorhydroxyquin
(Clioquinol), which chelates these metals in vitro, showed
slowing of
cognitive decline in the most severely affected of 32
Alzheimer's
disease patients studied."
http://www.nature.com/horizon/proteinfolding/background/treating.html
********************************************************************************************
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Home
Preface Brain Failure Notes Notes II
References pg. 1 References pg. 2
Nutritional Alternatives
Patricia's Protocol
Tauopathy
Discussion
Forum
Correspondence Newsletters Poems Memory Enhancement
********************************************************************************************
Questions or comments, contact "perpetualcommotion.com" at gmail.com
Updated: July 2, 2012
Inception: July 2, 2012